Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity
Antonella Giannantoni, Savino M Di Stasi, Vincenza Nardicchi, Alessandro Zucchi, Lara Macchioni, Vittorio Bini, Gianfrancesco Goracci, Massimo Porena, Antonella Giannantoni, Savino M Di Stasi, Vincenza Nardicchi, Alessandro Zucchi, Lara Macchioni, Vittorio Bini, Gianfrancesco Goracci, Massimo Porena
Abstract
Purpose: We investigated the effects of BTX-A on visceral afferent nerve transmission by measuring bladder tissue NGF levels in patients with neurogenic detrusor overactivity before and after intravesical treatment with BTX-A. We also compared the bladder tissue NGF content with clinical and urodynamic data.
Materials and methods: A total of 23 patients underwent clinical evaluation and urodynamics with detection of the UDC threshold, maximum pressure and maximum cystometric capacity before, and at the 1 and 3-month followups. Endoscopic bladder wall biopsies were also obtained at the same time points. NGF levels were measured in tissue homogenate by enzyme-linked immunosorbent assay (Promega, Madison, Wisconsin).
Results: At 1 and 3 months mean catheterization and incontinent episodes were significantly decreased (p <0.05 and <0.001, respectively). On urodynamics we detected a significant increase in the UDC threshold and maximum cystometric capacity, and a significant decrease in UDC maximum pressure at the 1 and 3-month follow-ups compared to baseline (each p <0.001). At the same time points we detected a significant decrease in NGF bladder tissue content (each p <0.02).
Conclusions: BTX-A intravesical treatment induces a state of NGF deprivation in bladder tissue that persists at least up to 3 months. As caused by BTX-A, the decrease in acetylcholine release at the presynaptic level may induce a decrease in detrusor contractility and in NGF production by the detrusor muscle. Alternatively BTX-A can decrease the bladder level of neurotransmitters that normally modulate NGF production and release.
Source: PubMed
Aankomende klinische onderzoeken
-
NCT07640607Nog niet aan het wervenCentrale sensibilisatie | Pijn perceptie | Kwantitatieve sensorische testen | Fibromyalgie (FM) | DRUK PIJN DREMPEL
-
NCT07640620Werving
-
NCT07640633Nog niet aan het wervenFMT for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients (FMT-FIT)Gastro-intestinale disfunctie | Voedingsintolerantie | Ernstig zieke patiënten op de intensive care
-
NCT07640646WervingHartoperatie | Chronische postoperatieve pijn
-
NCT07640659Nog niet aan het wervenColitis ulcerosa (UC)
-
NCT07640672Nog niet aan het wervenDakloos | Psychiatrische stoornissen | Daklozen | Drugsmisbruik / afhankelijkheid | Wond en verwondingen | Chronische wondverzorging | Omgevingsfactoren | Milieugezondheid
-
NCT07640685Nog niet aan het wervenSlaap | Herstel | Atletische prestatie
-
NCT07640698Nog niet aan het wervenMultiple sclerose (MS) | Televerpleging
-
NCT07640711WervingRuggengraat letsel | Quadriplegie | Tetraplegia C1-C4
-
NCT07640737Nog niet aan het wervenNeuro-endocriene (NE) tumoren | Geavanceerde NET van GI-oorsprong
-
NCT07640750Nog niet aan het wervenChronische myeloïde leukemie | Chronische myeloïde leukemie - chronische fase
-
NCT07640776Nog niet aan het wervenLower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)